Covid-19 pandemic: WHO panel for use of Pfizer jab on 5-11-year olds

The recommendation comes after the Strategic Advisory Group of Experts (SAGE) on immunisation held a meeting on Wednesday

Pfizer
Photo: Reuters
Reuters
1 min read Last Updated : Jan 22 2022 | 1:44 AM IST
The World Health Organisation on Friday recommended extending the use of a reduced dosage of Pfizer's COVID-19 vaccine to children aged 5 to 11 years old.

The recommendation comes after the Strategic Advisory Group of Experts (SAGE) on immunisation held a meeting on Wednesday to evaluate the vaccine. It is currently recommended for use in people aged 12 and above.

The recommended dosage for the young is 10 micrograms instead of 30 micrograms offered to those 12 and older.

Sub-lineage of Omicron under study in UK

Also Read

 
The UK health authorities on Friday said they will be conducting further analysis into a sub-lineage of the Omicron variant of Covid-19 after designating it a variant under investigation (VUI). The UK Health Security Agency which monitors data related to the pandemic, said the sub-lineage known as BA.2 shows a low number of cases in the country, with the original Omicron lineage BA.1 still dominant. VUI is the initial step before being termed variant of concern. (PTI)



One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

Next Story